Hot Picks: Cancer-focused biotech firms gain attention as key clinical results near [BNN Bloomberg (Canada)]
Revolution Medicines, Inc. (RVMD)
Company Research
Source: BNN Bloomberg
BNN Bloomberg spoke with Robert Driscoll, senior vice-president of equity research at Wedbush, about why he sees potential upside in Revolution Medicines, Monte Rosa Therapeutics and Kura Oncology. Key Takeaways Revolution Medicines is advancing therapies for RAS-mutated cancers, with key data next year that could support regulatory filings. The company has shown promising results in pancreatic and lung cancers and holds a priority review voucher to speed potential approvals. Monte Rosa Therapeutics is developing molecular glue drugs with prostate cancer data due shortly and a Novartis partnership in autoimmune disease. Kura Oncology recently won FDA approval for KOMZIFTI in late-line AML, with earlier-line data due at December's major hematology meeting. All three companies have multiple clinical or regulatory catalysts that could shift investor sentiment over the next year. Read the full transcript below: ANDREW: Our guest covers the biotech industry, and that's the
Show less
Read more
Impact Snapshot
Event Time:
RVMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVMD alerts
High impacting Revolution Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
RVMD
News
- Healthcare stocks are red-hot. Here are 3 picks from a fund manager up 41% this year. [Business Insider]Business Insider
- Revolution Medicines (NASDAQ:RVMD) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.MarketBeat
- Revolution Medicines (NASDAQ:RVMD) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $75.00 price target on the stock.MarketBeat
- Revolution Medicines, Inc. (RVMD) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript [Seeking Alpha]Seeking Alpha
- Revolution Medicines (RVMD): Assessing Valuation After Recent 28% Monthly Share Price Surge [Yahoo! Finance]Yahoo! Finance
RVMD
Earnings
- 11/5/25 - Miss
RVMD
Sec Filings
- 11/26/25 - Form 4
- 11/26/25 - Form 4
- 11/25/25 - Form 144
- RVMD's page on the SEC website